CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
GDX012 is a novel cell therapy developed for the treatment of certain types of cancer, including Acute Myeloid Leukemia (AML). The main aims...
Phase 1, Phase 2
Birmingham, Alabama, United States and 13 other locations
in future studies in study participants diagnosed with acute myeloid leukemia (AML), myelodysplastic syndromes with increased blasts grade 2...
Phase 1, Phase 2
Birmingham, Alabama, United States and 33 other locations
phase I study to determine the maximum tolerated dose of adding Loncastuximab Tesirine to Aclabrutinib in the treatment of chronic lymphocytic leukemia...
Phase 1
Birmingham, Alabama, United States
chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (rux...
Phase 2
Birmingham, Alabama, United States and 110 other locations
This study evaluates KRT-232, a novel oral small molecule inhibitor of MDM2, for the treatment of patients with Ph+ Chronic Myeloid Leukemia...
Phase 1, Phase 2
Birmingham, Alabama, United States and 25 other locations
safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia...
Phase 1, Phase 2
Birmingham, Alabama, United States and 34 other locations
The purpose of this study is to determine the recommended Phase 2 dose (RP2D) candidate(s) of bleximenib in combination with AML directed therapies (...
Phase 1
Birmingham, Alabama, United States and 32 other locations
This is a Phase 1-2, multicenter, international, single-arm, open-label study designed to identify a recommended dose of bosutinib administered orall...
Phase 1, Phase 2
Birmingham, Alabama, United States and 58 other locations
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding sit...
Phase 2
Birmingham, Alabama, United States and 79 other locations
A multi-center, open-label, randomized, phase Ib study to evaluate the pharmacokinetics (PK) of HQP1351 and to determine the recommended phase 2 dose...
Phase 1
Birmingham, Alabama, United States and 7 other locations
Clinical trials
Research sites
Resources
Legal